Celgene Co. (NASDAQ:CELG) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday. The brokerage presently has a $134.80 price target on the biopharmaceutical company’s stock. Vetr‘s price target points to a potential upside of 15.12% from the company’s previous close. A number […]
